Allarity Therapeutics (ALLR) vs Karyopharm Therapeutics (KPTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Allarity Therapeutics (ALLR) has outperformed Karyopharm Therapeutics (KPTI) over the past year, losing 42.2% versus a loss of 89.8%. Allarity Therapeutics is the larger company by market cap ($16.0 million vs $13.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | KPTI |
|---|---|---|
| Share price | $1.01 | $0.5782 |
| Market cap | $15.99M | $13.11M |
| 1-day change | +2.35% | -3.63% |
| YTD return | -9.08% | -91.85% |
| 1-year return | -42.24% | -89.83% |
| 5-year return | — | -99.28% |
| EPS (TTM) | $-0.79 | $-14.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.84 | $10.99 |
| 52-week low | $0.769 | $0.5652 |
| Distance from 52-week high | -45.38% | -94.74% |
| Analyst consensus | none | none |
| Avg. price target upside | +994.53% | +1153.89% |
| Average volume | 90.75K | 1.71M |
| Shares outstanding | 15.91M | 22.68M |
| Employees | 7 | 228 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLR has outperformed KPTI by 47.6 percentage points over the past year.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Karyopharm Therapeutics
KPTI stock →Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Health Care · Biotechnology: Pharmaceutical Preparations · 228 employees
ALLR vs KPTI FAQ
Which is bigger, Allarity Therapeutics or Karyopharm Therapeutics?
Allarity Therapeutics (ALLR) is larger, with a market capitalization of $15.99M compared with $13.11M for Karyopharm Therapeutics (KPTI).
Which stock has performed better over the past year, ALLR or KPTI?
ALLR returned -42.24% over the past 12 months, compared with -89.83% for KPTI (price return, excluding dividends). Past performance does not predict future results.
Are Allarity Therapeutics and Karyopharm Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.